Examine the Epidemiology and Outcomes of Transitions From PD-to-HD in Canada (UPLIFT-PD CORR)

Understand, Plan and Improve Care and Wellbeing of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis, Epidemiology (Phase 1)

Transitions from peritoneal dialysis to hemodialysis are common during kidney replacement therapy and may be associated with adverse outcomes. However, the incidence, predictors, and outcomes of PD-to-HD transitions at a national level remain incompletely characterized.

This study will use Canadian dialysis and hospitalization databases to examine the epidemiology and outcomes of PD-to-HD transitions among adults initiating dialysis in Canada. The study will evaluate transition incidence, predictors, and post-transition outcomes including mortality, transplantation, modality changes, and hospitalizations.

Study Overview

• Status: Active, not recruiting
• Conditions: Hemodialysis; Peritoneal Dialysis (PD); Kidney Replacement Therapy

• Study Type: Observational
• Enrollment (Estimated): 17000

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montreal, Quebec, Canada, H1T 2M4
      • CIUSSS de l'Est-de-l'ile de Montréal

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adults initiating dialysis in Canada between 2005 and 2018 who received peritoneal dialysis for at least 30 consecutive days, identified using the Canadian Organ Replacement Register (CORR) and linked administrative databases.

Description

Inclusion Criteria:

• Adults (≥18 years)
• Dialysis initiation in Canada between January 1, 2005 and December 31, 2018
• Peritoneal dialysis duration >30 consecutive days

Exclusion Criteria:

• Dialysis initiation in Quebec or Manitoba during the study period
• Dialysis initiation in a foreign country
• Missing data on initial dialysis modality
• Pre-emptive kidney transplantation

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patient receiving peritoneal dialysis with transfer to hemodialysis; Adults initiating dialysis in Canada between 2005 and 2018 who received peritoneal dialysis and experience a transfer to hemodialysis for 2 or more consecutive days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of transfer from peritoneal dialysis to hemodialysis	Measured as cumulative incidence and incidence rate of transitions following initiation of PD and censored at time of death, kidney transplantation, transfer home hemodialysis, or administrative end of follow-up.	From PD initiation until 1-year after PD start Also assessed at from PD initation until 2- and 5-year after PD start.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All-cause mortality after transfer from peritoneal dialysis to hemodialysis	Censored for kidney transplantation, transfer home hemodialysis, return to PD or administrative end of follow-up December 31st, 2018	From first day after transfer up to 1-year post transfert. Also assessed ad 2- and 5-year post transfer
Return to Peritoneal Dialysis	Defined as ≥1 consecutive day of peritoneal dialysis after transition and censored at time of death, kidney transplantation, transfer home hemodialysis or administrative end of follow-up December 31st, 2018)	From first day after transfer to HD up to 180-day post transfer. Also measured at 90- and 365-day post transfer.
Transfer to Home Hemodialysis	Defined as ≥30 consecutive days of home hemodialysis censored at time of death, kidney transplantation, return to PD or administrative end of follow-up December 31st, 2018)	From first day after transfer to HD until 180-day post transfer. Also measured at 90- and 365-day post transfer

Collaborators and Investigators

• Sponsor: Ciusss de L'Est de l'Île de Montréal

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2005
• Primary Completion (Actual): December 31, 2019
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: February 20, 2026
• First Submitted That Met QC Criteria: March 13, 2026
• First Posted (Actual): March 17, 2026

Study Record Updates

• Last Update Posted (Actual): March 17, 2026
• Last Update Submitted That Met QC Criteria: March 13, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Transition; Transfer to hemodialysis
• Other Study ID Numbers: 2021-2531; 203760_1 (Other Grant/Funding Number: CIHR)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Based on restriction from the Canadian Institute for Health Information and our third party agreement

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No